AUR-AD9F-TTM3-A-1-1-R-A542-39
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.570
- OXIDATIVE_PHOSPHORYLATION+0.570
- PANCREAS_BETA_CELLS+0.520
- FATTY_ACID_METABOLISM+0.480
- ADIPOGENESIS+0.460
- XENOBIOTIC_METABOLISM+0.450
- MTORC1_SIGNALING+0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.440
- BILE_ACID_METABOLISM+0.400
- ANDROGEN_RESPONSE+0.380
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.350
- INTERFERON_ALPHA_RESPONSE-0.330
- WNT_BETA_CATENIN_SIGNALING-0.310
- ALLOGRAFT_REJECTION-0.280
- TGF_BETA_SIGNALING-0.260
- INFLAMMATORY_RESPONSE-0.220
- G2M_CHECKPOINT-0.210
- TNFA_SIGNALING_VIA_NFKB-0.210
- E2F_TARGETS-0.190
- NOTCH_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AD9I-TTM3-A-1-1-R-A542-39 | — | C | 0.852 |
| 2 | 148130 | EPN | Supratentorial EPN | 0.815 |
| 3 | SRR8518204 | — | F | 0.798 |
| 4 | TCGA-A8-A07P-01A-11R-A00Z-07 | — | B | 0.795 |
| 5 | SRR4296070 | — | cohortA1 | 0.787 |
| 6 | TCGA-73-4659-01A-01R-1206-07 | — | cohortA3 | 0.783 |
| 7 | SRR6013485 | — | cohortA4 | 0.772 |
| 8 | e94b6daf-3aed-4496-b64b-1b1a7d8e2011 | — | — | 0.769 |
| 9 | TCGA-E2-A14O-01A-31R-A115-07 | — | B | 0.767 |
| 10 | AUR-AD9F-TTM1-A-1-1-R-A542-39 | — | C | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.570 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.570 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.520 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.480 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.460 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.450 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.440 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.340 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |